Advertisement

Topics

Oryzon Genomics Company Profile

14:57 EST 9th December 2018 | BioPortfolio

Oryzon genomics is a functional genomics company based in Barcelona, Spain. It was launched in 2001 as a spin-off of the Spanish National Research Council (CSIC) and the University of Barcelona, and has an international staff of 30 highly qualified scientists.

Location

Parc Científic de BarcelonaC/Josep Samitier 1-5
Barcelona
08028
Spain

Contact

Phone: 34 93 403 71 96
Fax: 34 93 403 47 92
Email: info@oryzon.com


News Articles [409 Associated News Articles listed on BioPortfolio]

Oryzon Genomics (ORY) - Awaiting for eventful 2019

Edison Investment Research - Pharmaceutical & healthcare - Oryzon Genomics: The next year is shaping up to be transformative for Oryzon with two data readouts from Phase IIa trials with ORY-2001 in Al...

Edison issues outlook on Oryzon Genomics (ORY)

Dow Jones received a payment from EQS/DGAP to publish this press release. Edison Investment Research Limited Edison issues outlook on Oryzon Genomics (ORY) 18-Jul-2018 / 16:01 GMT/BST London, UK, ...

Oryzon Genomics (ORY) - Ramping up R&D activity; catalysts in 2019

Edison Investment Research - Pharmaceutical & healthcare - Oryzon Genomics: The €13m (gross) private placement announced on 30 October 2018 will support Oryzon’s expanding R&D programme...

Oryzon completes funding

10X Genomics Prepares to Hire 200 New Employees, Move into Larger Facility

Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately-held companies in the region with an earnings increase of more than 2,000 percent over a three-year period.

HIGHLIGHTS: Sanfeliu leaves Ysios, Bionure round of funding, Alzheimer research, milestones at Oryzon and Spherium, results of publicly traded companies

HIGHLIGHTS: Sanfeliu leaves Ysios, Bionure round of funding, Alzheimer research, milestones at Oryzon and Spherium, results of publicly traded companies

ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2018

-$0.01/share for the 9 months ended September 30th MADRID, Spain and CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage bi...

ORYZON announces First Patients in the UK in ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

MADRID, Spain and CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code:ES0167733015) (BME:ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to...

Drugs and Medications [0 Results]

None

Clinical Trials [93 Associated Clinical Trials listed on BioPortfolio]

Electronic Medical Records and Genomics (eMERGE) Phase III

The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clini...

Genomics and Postoperative Atrial Fibrillation

This research study is done to find out if genetic make up of a person plays a role in complications and recovery after the Coronary Artery Bypass Graft (CABG) operation. As you may be aw...

Microfluidics and Transcriptomics in Post Solid Organ Transplant Patients

The field of genomics is an exciting new field being applied in medicine. Its use in treating some cancers, sepsis and burn patients has been very promising. As knowledge of genomics and a...

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

This pilot clinical trial studies whether using high throughput drug sensitivity and genomics data is feasible in developing individualized treatment in patients with multiple myeloma or p...

GENetic Education Risk Assessment and TEsting Study

The goal of the GENERATE study is to improve genetic testing and cancer prevention in family members of pancreatic cancer patients with identified genetic mutations (inherited changes). Th...

Companies [415 Associated Companies listed on BioPortfolio]

Oryzon Genomics

Oryzon genomics is a functional genomics company based in Barcelona, Spain. It was launched in 2001 as a spin-off of the Spanish National Research Council (CSIC) and the University of Barcelona, and h...

Genomics in Business

In 2003 Keygene initiated the first edition of Genomics in Business. It was the first conference to focus on the existing and future applications of genomics in the Agro-Food industry. With participan...

Genomics One Corporation

Genomics One is a fully integrated biotechnology company committed to the creation of shareholder value through innovation in the fields of genomics, proteomics and mono-clonal antibodies. The mission...

Center for Genomics and Bioinformatics

Center for Genomics and Bioinformatics The Center for Genomics and Bioinformatics (CGB) was launched in 1997 as a new academic department at the Karolinska Institute. Since then, the department has be...

Front Line Genomics

At Front Line Genomics our mission is to help deliver the benefits of genomics faster. Through our website, our magazine and the Festivals of Genomics, we support scientists, clin...

More Information about "Oryzon Genomics" on BioPortfolio

We have published hundreds of Oryzon Genomics news stories on BioPortfolio along with dozens of Oryzon Genomics Clinical Trials and PubMed Articles about Oryzon Genomics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oryzon Genomics Companies in our database. You can also find out about relevant Oryzon Genomics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record